TriangleDISEASE & TREATMENT SETTING
ZEJULA: advanced peritoneal cancer with BRCA mutation (first-line)
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
• for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: o a deleterious or suspected deleterious BRCA mutation, and/or o genomic instability.
Broader topic: Malignant Peritoneal Neoplasm
- Source population
- Not part of this definition
- Disease extent
- advanced
- Treatment line
- first-line
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- gene
- BRCA
- alteration
- mutation
- status
- present
- prior therapy
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for ZEJULA (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: o a deleterious or suspected deleterious BRCA mutation, and/or o genomic instability.
Study evidence for this setting
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice